Tags : Human-First Discovery Platform

Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome

Shots: Finch and Takeda will leverage Finch’s platform to develop microbiome-based therapeutics targeting Crohn’s disease. Takeda to get exclusive worldwide rights to commercialize rationally selected microbiota (RSM) therapies developed for Crohn’s disease In 2107, Takeda and Finch collaborated to jointly develop FIN-524 for ulcerative colitis under which Finch has received $10M upfront, milestones & royalties […]Read More